Information de reference pour ce titreAccession Number: | 01445466-201512150-00011.
|
Author: | Zaikova, Olga MD, PhD; Hall, Kirsten Sundby MD, PhD; Styring, Emelie MD, PhD; Eriksson, Mikael MD, PhD; Trovik, Clement S. MD, PhD; Bergh, Peter MD, PhD; Bjerkehagen, Bodil MD, PhD; Skorpil, Mikael MD; Weedon-Fekjaer, Harald PhD; Bauer, Henrik C.F. MD, PhD
|
Institution: | (1)Department of Orthopedics, Oslo University Hospital, The Norwegian Radium Hospital, Norway (2)Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Norway (3)Department of Orthopedics, Lund University and Skane University Hospital, Lund, Sweden (4)Department of Oncology, Skane University Hospital, and Lund University, Lund, Sweden (5)Department of Orthopaedics, Haukeland University Hospital, Bergen, Norway (6)Department of Orthopaedics, Sahlgren University Hospital, Gothenburg, Sweden (7)Department of Pathology, Oslo University Hospital, The Norwegian Radium Hospital, Norway (8)Department of Molecular Medicine and Surgery, Diagnostic Radiology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden (9)Oslo Center for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway (10)Department of Molecular Medicine and Surgery, Section for Orthopaedics and Sports Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
|
Title: | |
Source: | Journal of Surgical Oncology. 112(8):853-860, December 15, 2015.
|
Abstract: | Aims: The objectives of this study were to present changes in referral patterns, treatment and survival in patients with high-grade malignant bone sarcoma in Sweden and Norway based on data in the Scandinavian Sarcoma Group (SSG) Central Register.
Method: Data on 1,437 patients with diagnosis 1986-2010 was analyzed.
Results: Osteosarcoma was the most frequentl diagnosis (45%), followed by Ewing sarcoma (21%) and chondrosarcoma (17%). Thirty-one percent of Swedish and 41% of Norwegian patients had tumors in the axial skeleton. Eighty-six percent of extremity tumors and 66% of axial tumors were referred to a sarcoma center prior to unplanned surgery or biopsy. During the past decade, limb salvage surgery has risen from under 50% to over 80%. Five-year overall survival in non-metastatic osteosarcoma was 70% for extremity tumors, and 35% for axial tumors. No improvement in osteosarcoma survival was observed during the last decade. Five-year survival in Ewing sarcoma improved from 50% to 69%.
Conclusion: Referral patterns in bone sarcomas have improved. However, greater efforts should be dedicated to improving referral of patients with possible tumors in the axial skeleton to multidisciplinary teams (MDTs). Overall survival of patients with high-grade malignant bone sarcomas in Sweden and Norway is in line with other reports. J. Surg. Oncol. 2015;112:853-860. (C) 2015 Wiley Periodicals, Inc.
(C) 2015 John Wiley & Sons, Ltd
|
Author Keywords: | osteosarcoma; chondrosarcoma; Ewing sarcoma; bone sarcoma; SSG; referral pattern; overall survival.
|
References: | 1. Whelan JS, Jinks RC, McTiernan A, et al.: Survival from high-grade localised extremity osteosarcoma: Combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Annals Oncol 2012; 23:1607-1616.
2. Stiller CA, Trama A, Serraino D, et al.: Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project. Eur Journal Cancer 2013; 49:684-695.
3. Ferrari S, Smeland S, Mercuri M, et al.: Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23:8845-8852.
4. Boye K, Del Prever AB, Eriksson M, et al.: High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study. Pediatr Blood Cancer 2014; 61:840-845.
5. Smeland S, Muller C, Alvegard TA, et al.: Scandinavian sarcoma group osteosarcoma study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 2003; 39:488-494.
6. Whelan JS, Bielack SS, Marina N, et al.: EURAMOS-1, an international randomised study for osteosarcoma: Results from pre-randomisation treatment. Ann Oncol 2015; 26:407-414.
7. Saeter G, Alvegard TA, Elomaa I, et al.: Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: A Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9:1766-1775.
8. Maretty-Nielsen K, Aggerholm-Pedersen N, Keller J, et al.: Population-based Aarhus Sarcoma Registry: Validity, completeness of registration, and incidence of bone and soft tissue sarcomas in western Denmark. Clin Epidemiol 2013; 5:45-56.
9. Ljungman G, Jakobson A, Behrendtz M, et al.: Incidence and survival analyses in children with solid tumours diagnosed in Sweden between 1983 and 2007. Acta Paediatrica 2011; 100:750-757.
10. Damron TA, Ward WG, Stewart A.: Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthopd Relat Res 2007; 459:40-47.
11. Brader P, Abramson SJ, Price AP, et al.: Do characteristics of pulmonary nodules on computed tomography in children with known osteosarcoma help distinguish whether the nodules are malignant or benign? J Pediatr Surg 2011; 46:729-735.
12. Steven Gitelis MCC.: Pulmonary micronodules do not impact survival in young sarcoma patients CTOS. NY, USA: 2013.
13. Allison DC, Carney SC, Ahlmann ER, et al.: A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012; 2012:704872.
14. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al.: The clinical approach towards chondrosarcoma. Oncologist 2008; 13:320-329.
15. Sampo M, Koivikko M, Taskinen M, et al.: Incidence, epidemiology and treatment results of osteosarcoma in Finland-A nationwide population-based study. Acta Oncologica 2011; 50:1206-1214.
16. Mirabello L, Troisi RJ, Savage SA.: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer 2009; 115:1531-1543.
17. Picci P, Mercuri M, Ferrari S, et al.: Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Annals Oncol 2010; 21:1366-1373.
18. Whelan J, McTiernan A, Cooper N, et al.: Incidence and survival of malignant bone sarcomas in England 1979-2007. Int J Cancer 2012; 131:E508-E517.
19. Hagleitner MM, Hoogerbrugge PM, van der Graaf WT, et al.: Age as prognostic factor in patients with osteosarcoma. Bone 2011; 49:1173-1177.
20. Mankin HJ, Hornicek FJ, Rosenberg AE, et al.: Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004; 286-291.
21. Ferrari S, Bertoni F, Mercuri M, et al.: Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: An analysis of 300 patients treated at the Rizzoli Institute. Annals Oncol 2001; 12:1145-1150.
22. Collins M, Wilhelm M, Conyers R, et al.: Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: Findings from a meta-analysis. J Clin Oncol 2013; 31:2303-2312.
23. Serlo JA, Helenius IJ, Sampo M, et al.: Ewing's sarcoma family of tumors in Finland during 1990-2009: A population-based study. Acta Oncologica 2013; 52:767-775.
24. Ahmed SK, Robinson SI, Okuno SH, et al.: Adult ewing sarcoma: Survival and local control outcomes in 102 patients with localized disease. Sarcoma 2013; 2013:681425.
25. Letourneau PA, Shackett B, Xiao L, et al.: Resection of pulmonary metastases in pediatric patients with Ewing sarcoma improves survival. J Pediatr Surg 2011; 46:332-335.
26. Cotterill SJ, Ahrens S, Paulussen M, et al.: Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18:3108-3114.
27. Ferrari S, Sundby Hall K, Luksch R, et al.: Nonmetastatic Ewing family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group, III., protocol. Ann Oncol 2011; 22:1221-1227.
28. Elomaa I, Blomqvist CP, Saeter G, et al.: Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 2000; 36:875-880.
29. Luksch R, Tienghi A, Hall KS, et al.: Primary metastatic Ewing's family tumors: Results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol 2012; 23:2970-2976.
30. Pradhan A, Grimer RJ, Spooner D, et al.: Oncological outcomes of patients with Ewing's sarcoma: Is there a difference between skeletal and extra-skeletal Ewing's sarcoma? J Bone Joint Surg Br Vol 2011; 93:531-536.
|
Language: | English.
|
Document Type: | Research Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0022-4790
|
DOI Number: | https://dx.doi.org/10.1002/jso.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|